| L01XX85 |
L01XX85 Idroxioleic acid |
| L01XX86 |
L01XX86 Calaspargase pegol |
| L01XY |
L01XY Combinations of antineoplastic agents |
| L01XY01 |
L01XY01 cytarabine and daunorubicin |
| L01XY02 |
L01XY02 Pertuzumab and trastuzumab |
| L02 |
L02 Endocrine Therapy |
| L02A |
L02A Hormones and Related Agents |
| L02AA |
L02AA Estrogens |
| L02AA01 |
L02AA01 Diethylstilbestrol |
| L02AA02 |
L02AA02 Polyestradiol phosphate |
| L02AA03 |
L02AA03 Ethinylestradiol |
| L02AA04 |
L02AA04 Fosfestrol |
| L02AB |
L02AB Progestogens |
| L02AB01 |
L02AB01 Megestrol |
| L02AB02 |
L02AB02 Medroxyprogesterone |
| L02AB03 |
L02AB03 Gestonorone |
| L02AE |
L02AE Gonadotropin releasing hormone analogues |
| L02AE01 |
L02AE01 Buserelin |
| L02AE02 |
L02AE02 Leuprorelin |
| L02AE03 |
L02AE03 Goserelin |
| L02AE04 |
L02AE04 Triptorelin |
| L02AE05 |
L02AE05 Histrelin |
| L02AE51 |
L02AE51 Leuprorelin and bicalutamide |
| L02AX |
L02AX Other hormones |
| L02B |
L02B Hormone Antagonists and Related Agents |
| L02BA |
L02BA Anti-estrogens |
| L02BA01 |
L02BA01 Tamoxifen |
| L02BA02 |
L02BA02 Toremifene |
| L02BA03 |
L02BA03 Fulvestrant |
| L02BB |
L02BB Anti-androgens |